Agencies has add call on Fortis Healthcare with a target price of Rs 299. The current market price of . is Rs 258.15. Time period given by analyst is one year when Ltd. price can reach defined target.
Fortis Healthcare Ltd., incorporated in the year 1996, is a Mid Cap company (having a market cap of Rs 19466.60 Crore) operating in Hospitals & Allied Services sector.
Fortis Healthcare Ltd. key Products/Revenue Segments include HealthCare Services, Other Operating Revenue, Lease Rentals, Pharmaceuticals and Export Incentives for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 1508.55 Crore, up 8.99 % from last quarter Total Income of Rs 1384.09 Crore and up 6.37 % from last year same quarter Total Income of Rs 1418.15 Crore. Company reported net profit after tax of Rs 124.29 Crore in latest quarter.
Investment Rationale
The stock currently trades at EV/EBITDA of 18.1x FY23E and 15.0x FY24E. The brokerage remains optimistic on the outlook considering strong growth in hospitals with increasing occupancy and ARPOB, inherent traction in the diagnostic industry for SRL, and cost- control initiatives employed by the current management. Maintain ADD on the stock with a target price of Rs299/share based on SoTP valuation of FY24E.
Promoter/FII Holdings
Promoters held 31.17 per cent stake in the company as of 30-Jun-2022, while FIIs owned 29.66 per cent, DIIs 17.6 per cent.
Fortis Healthcare Ltd., incorporated in the year 1996, is a Mid Cap company (having a market cap of Rs 19466.60 Crore) operating in Hospitals & Allied Services sector.
Fortis Healthcare Ltd. key Products/Revenue Segments include HealthCare Services, Other Operating Revenue, Lease Rentals, Pharmaceuticals and Export Incentives for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-06-2022, the company reported a Consolidated Total Income of Rs 1508.55 Crore, up 8.99 % from last quarter Total Income of Rs 1384.09 Crore and up 6.37 % from last year same quarter Total Income of Rs 1418.15 Crore. Company reported net profit after tax of Rs 124.29 Crore in latest quarter.
Investment Rationale
The stock currently trades at EV/EBITDA of 18.1x FY23E and 15.0x FY24E. The brokerage remains optimistic on the outlook considering strong growth in hospitals with increasing occupancy and ARPOB, inherent traction in the diagnostic industry for SRL, and cost- control initiatives employed by the current management. Maintain ADD on the stock with a target price of Rs299/share based on SoTP valuation of FY24E.
Promoter/FII Holdings
Promoters held 31.17 per cent stake in the company as of 30-Jun-2022, while FIIs owned 29.66 per cent, DIIs 17.6 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by